SeaStar Medical (ICU)

Executive Summary

SeaStar Medical is a commercial-stage medical technology company pioneering a novel immunomodulation approach in critical care. Its core product, the Selective Cytopheretic Device (SCD), is designed to selectively calm the cytokine storm that leads to organ failure and death in critically ill patients. In July 2024, the company received FDA approval for its first product, Quelimmune, for pediatric patients. The device targets a significant unmet need in conditions such as Acute Kidney Injury (AKI) and sepsis, where hyperinflammation drives morbidity and mortality. By selectively targeting activated neutrophils and monocytes, SCD aims to restore immune homeostasis without broad immunosuppression.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for adult Acute Kidney Injury indication70% success
• Q2 2027Pivotal trial results for SCD in sepsis or COVID-1950% success
• Q3 2026Strategic partnership or licensing deal for international markets60% success